Alexion Pharmaceuticals Inc (ALXN)

126.00
NASDAQ : Health Care
Prev Close 126.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 110.56 / 193.45
Avg Volume 2.21M
Exchange NASDAQ
Shares Outstanding 224.25M
Market Cap 28.17B
EPS 0.70
P/E Ratio 306.39
Div & Yield N.A. (N.A)

Latest News

Healthcare Stocks Help Nasdaq Reach New Heights

Healthcare Stocks Help Nasdaq Reach New Heights

The Nasdaq rose 0.7% to an all-time high of 5,403. The S&P 500 was up 0.3%, and the Dow Jones Industrial Average gained 0.2%.

Alexion To Present At The Citi 2016 Global Healthcare Conference

Alexion To Present At The Citi 2016 Global Healthcare Conference

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016 at 11:00 a.

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Analysts' Actions -- Goldman Sachs, Johnson & Johnson, Pfizer and More

Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Alexion Pharmaceuticals, Inc.

New Data From Global AHUS Registry Presented At ASN 2016 Show A Three-Fold Reduction In Post-Transplant Dialysis In Patients Initiating Soliris® (eculizumab) Treatment Prior To Transplant Compared To Initiating Treatment Post-Transplant

New Data From Global AHUS Registry Presented At ASN 2016 Show A Three-Fold Reduction In Post-Transplant Dialysis In Patients Initiating Soliris® (eculizumab) Treatment Prior To Transplant Compared To Initiating Treatment Post-Transplant

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that...

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Alexion Receives NASDAQ Notification Related To The Late Filing Of Form 10-Q

Alexion Receives NASDAQ Notification Related To The Late Filing Of Form 10-Q

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it received a notification letter on November 15, 2016 from The NASDAQ Stock Market ("NASDAQ").

New Long-Term Data Presented At AASLD Show Reduction In Liver Fibrosis And Cirrhosis In A Cohort Of Patients With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma® (sebelipase Alfa)

New Long-Term Data Presented At AASLD Show Reduction In Liver Fibrosis And Cirrhosis In A Cohort Of Patients With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma® (sebelipase Alfa)

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that researchers presented new longer-term data from an ongoing, open-label extension of the pivotal Phase 3 ARISE trial of Kanuma ® (sebelipase alfa) in...

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Alexion Pharmaceuticals, Inc.

Alexion Drug Sale Practices Target of Internal Investigation

Alexion Drug Sale Practices Target of Internal Investigation

Alexion Pharmaceuticals disclosed Wednesday its board of directors is investigating allegations of improper sales practices tied to its top-selling drug Soliris.

Alexion Provides Update On Form 10-Q Filing

Alexion Provides Update On Form 10-Q Filing

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.

Researchers To Present New Phase 1/2 Data On ALXN1210 In Patients With PNH At ASH 2016 Annual Meeting

Researchers To Present New Phase 1/2 Data On ALXN1210 In Patients With PNH At ASH 2016 Annual Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present new interim data from a Phase 1/2 dose-escalation study of ALXN1210, the Company's investigational, highly innovative longer-acting...

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Here's a window into what institutional investors may be doing and how to profit from that.

Alexion Pharmaceuticals Surges on Heavy Trade

Alexion Pharmaceuticals Surges on Heavy Trade

Consider buying this biotech stock on weakness after a strong run higher Thursday.

Alexion Pharmaceuticals (ALXN) Stock Soars on Q3 Beat, Outlook

Alexion Pharmaceuticals (ALXN) Stock Soars on Q3 Beat, Outlook

Alexion Pharmaceuticals (ALXN) posted 2016 third-quarter results that surpassed Wall Street's expectations before today's market open.

Alexion Initiates Simultaneous Registration Trials Of ALXN1210 For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Initiates Simultaneous Registration Trials Of ALXN1210 For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement.

Alexion Reports Third Quarter 2016 Results

Alexion Reports Third Quarter 2016 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2016.